Hemex

Co-founders Franziska Stemmler, as CEO, and Pascal Winnen, as Managing Director EU, run the firm and its investment decisions. Winnen's additional role as Chairman of portfolio company Scailyte AG suggests he leads technical and governance oversight on specific deals. The firm has not disclosed a separate investment committee, indicating decisions likely rest with the founding partners.

Hemex sources primarily through its deep integration with the European life-science cluster ecosystem. The firm holds memberships in the Swiss Biotech Association, BioRN, HealthTech Cluster Switzerland, and the BEAM Alliance, giving it early visibility into academic spin-outs and pre-commercial ventures emerging from the Basel-Zurich-Rhine-Neckar corridor. Its collaborative project work with the Swiss Tropical and Public Health Institute provides an additional sourcing channel into global-health innovation.

Hemex appears to make direct equity investments into individual start-up and early-stage companies, as evidenced by board appointments at portfolio companies like Scailyte, Aspivix, and Resistell. There is no public record of the firm making fund commitments or acting as a limited partner in third-party venture funds.

The firm targets the earliest commercial stages — start-up and early seed — with a focus on ventures that are advancing toward clinical proof-of-concept. Its portfolio companies operate at the intersection of academic research and first regulatory milestones, particularly in diagnostics, medical devices, and novel therapeutic platforms.

The Hemex Investor Club is a co-investment vehicle or network based at the firm's Liestal headquarters, according to Altss research. It is structured as an adjacent entity that likely allows external accredited investors to participate alongside Hemex AG in specific deals, functioning as a syndicate rather than a commingled fund. The firm has not disclosed the club's membership size or minimum commitment terms.

Through its Investor Club structure, Hemex actively facilitates co-investment into its portfolio companies, suggesting openness to partnering with external investors on a deal-by-deal basis. The firm's board-level involvement model means external co-investors typically invest alongside Hemex's own governance oversight, rather than into a blind pool.

Based on its confirmed portfolio — single-cell analytics, atraumatic gynecology devices, and rapid antibiotic-susceptibility testing — and its BEAM Alliance membership, the firm concentrates strictly on human health. There is no evidence of investment in digital health outside clinical applications, nor in agricultural biotech or industrial biosciences, suggesting a deliberate exclusion of non-therapeutic and non-diagnostic verticals.